VRDN vs ZBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VRDN Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Viridian Therapeutics, Inc. Common Stock (VRDN) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, VRDN trades at 1.0x Forward P/E with -1781.4% operating margin (-63.5% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, VRDN sits in SURGE (16th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VRDN Revenue | ZBIO Revenue | VRDN Op. Margin | ZBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -394.5% | N/A | VRDN |
| FY2019 | $0M | N/A | -941.0% | N/A | VRDN |
| FY2020 | $0M | N/A | -10512.4% | N/A | VRDN |
| FY2021 | $0M | N/A | -2690.8% | N/A | VRDN |
| FY2022 | $0M | N/A | -7579.2% | N/A | VRDN |
| FY2023 | $0M | $50M | -81035.0% | -74.3% | ZBIO |
| FY2024 | $0M | $10M | -99018.2% | -3277.8% | ZBIO |
| FY2025 | $70M | $10M | -512.9% | -3830.6% | VRDN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VRDN | ZBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.5B | $1.9B | Larger Scale | VRDN |
| Trailing P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | VRDN |
| Forward P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | VRDN |
| Revenue Growth (YoY) Growth | -63.5% | -100.0% | Higher Growth | VRDN |
| Operating Margin (TTM) Profitability | -1781.4% | -2747.5% | Higher Margin | VRDN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -83.7% | -265.1% | Higher ROE | VRDN |
| 52-Week Range Position Momentum | 79% ($13โ$34) | 46% ($14โ$45) | Stronger Trend | VRDN |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 65% Vol | 1.16ฮฒ ยท 59% Vol | Lower Realized Risk | ZBIO |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 49.4 / 100 (HOLD) | Higher Composite | ZBIO |